Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

TM4SF1-CAR/EpCAM-CAR-expressing autologous T cells

A mixed preparation of allogeneic T lymphocytes that have been genetically modified to express either a chimeric antigen receptor (CAR) specific for the antigen transmembrane 4 L six family member 1 (TM4SF1) (CART-TM4SF1) or a CAR specific for epithelial cell adhesion molecule (EpCAM) (CART-EpCAM), with potential immunostimulating and antineoplastic activities. Upon administration of the TM4SF1-CAR/EpCAM-CAR-expressing autologous T cells, the TM4SF1-CAR-expressing autologous T cells specifically recognize and bind to TM4SF1-expressing tumor cells and the EpCAM-CAR-expressing autologous T cells specifically recognize and bind to EpCAM-expressing tumor cells, resulting in tumor cell lysis. TM4SF1 and EpCAM are expressed by a variety of tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CART-TM4SF1 cells/CART-EpCAM cells
autologous TM4SF1-targeting CAR T cells and EpCAM-targeting CAR T cells
TM4SF1-CAR autologous T cells/EpCAM-CAR autologous T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search